Human Trials

Trial to test cancer combo in adults and children with leukaemia

The Combinations Alliance, a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network based at University of Birmingham, has launched a clinical trial testing a new treatment combination in patients with leukaemia.

Janssen begins phase 1b/2 clinical trial to assess multiple myeloma treatment

Janssen has commenced a phase 1b/2 clinical development program to assess JNJ-68284528 (developed based on Legend’s LCAR-B38M), a chimeric antigen receptor T cell (CAR-T) therapy directed against B cell maturation antigen (BCMA), in patients with relapsed or refractory multiple myeloma.

Roche’s Tecentriq-chemo combo extends survival in phase 3 NSCLC trial

Roche said that its cancer immunotherapy Tecentriq (atezolizumab) in combination with chemotherapy as first-line of treatment improved survival of patients with advanced non-squamous non-small cell lung cancer (NSCLC) in a phase 3 trial.

ImmuPharma’s further phase III Lupuzor trial analysis shows positive results in Europe cohort

ImmuPharma said that additional analysis from its phase III trial of Lupuzor in patients with systemic Lupus erythematosus (SLE) has demonstrated positive results in the Europe cohort.

Midatech begins US clinical trial of MTX110 to treat DIPG

Midatech Pharma has commenced dosing in its first-in-human study with MTX110 for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive form of childhood brain cancer.

AstraZeneca’s Imfinzi extends survival rate in lung cancer patients

AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).

Midatech begins dosing in first human trial of cancer drug Q-Octreotide

Midatech has commenced initial dosing in the first in-human study of its sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly.

Janssen’s Erleada shown to reduce PSA progression by 94% in nmCRPC patients

Janssen Pharmaceutical's androgen receptor inhibitor Erleada (apalutamide) succeeded in a phase 3 trial by significantly cutting down the risk of prostate specific antigen (PSA) progression in patients having non-metastatic castration-resistant prostate cancer (nmCRPC).

Pfizer’s Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial

Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.